Jiangsu Cancer Institute & Hospital
Clinical trials sponsored by Jiangsu Cancer Institute & Hospital, explained in plain language.
-
New pill combo offers hope for Hard-to-Treat esophageal cancer
Disease control Recruiting nowThis study tests a chemotherapy pill (oral paclitaxel) combined with radiation for people with advanced esophageal cancer that cannot be removed by surgery. It is for patients aged 70 or older or those who cannot tolerate standard IV chemo. The goal is to see if this approach is …
Phase: PHASE2 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated May 26, 2026 10:56 UTC
-
New drug cocktail shows promise for inoperable lung cancer
Disease control Recruiting nowThis study tests whether adding two immune-boosting drugs (iparomlimab and tuvonralimab) to standard chemotherapy can shrink tumors in people with stage III lung cancer that cannot be surgically removed. About 33 adults aged 18–75 who have not had prior treatment for their cancer…
Phase: PHASE2 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
New hope for aggressive ovarian cancer: targeted drug combo enters trial
Disease control Recruiting nowThis study tests a new drug combination for people with a specific, high-risk type of ovarian cancer that has not yet been treated. The treatment includes a targeted drug (disitamab vedotin) plus standard chemotherapy and a blood-vessel blocker (bevacizumab). After initial treatm…
Phase: PHASE2 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated May 18, 2026 12:12 UTC